“As a result, we will be lowering our full year sales guidance for US Humira.”

In context

“ead studies versus Dupixent. We are also preparing for the global launch of giant cell arteritis, another new source of growth for Rinvoq. We received European approval earlier this month and expect FDA approval soon. The addition of this indication further rounds out Rinvoq's rheumatology label and gives patients with GCA access to a new compelling oral therapeutic option. Overall, Skyrizi and Rinvoq are demonstrating impressive results across all of their approved indications, and we will be raising our full year sales guidance for both products. Turning now to Humira, which delivered global sales of $1.1 billion down 49.5% on an operational basis, below our expectations, primarily due to faster share erosion from biosimilar competition as well as further molecule compression in the US. As a result, we will be lowering our full year sales guidance for US Humira. Moving to Oncology, where total revenues were $1.6 billion exceeding our expectations. Imbruvica global sales were $738 million down 11.9%, reflecting competitive dynamics in CLL. Venclexta global revenues were $665 million up 12.3% on an operational basis. This strong performance reflects continued momentum in CLL as well as shared leadership in frontline AML among patients who are ineligible for intensive induction chemotherapy. We also have an emerging commercial portfolio in solid tumors. This includes Elahere, our leading ADC for ovarian cancer with global sales of $179 million as well as Teliso-V, a potential new medicine for late line non-small cell lung cancer patients with US Regulatory approval and commercialization expected in the next couple of months. Teliso-V will be support”